Table 1 Characteristics of the index fragility fracture cohort
Characteristic | n (%)a |
|---|---|
Total number of patients in cohort | 115,776 |
Sex | |
 Women | 83,690 (72.3) |
 Men | 32,086 (27.7) |
Age (years) | |
 Median (IQR) | 81 (74–87) |
 Mean (SD) | 80.4 (8.3) |
 66–70 | 17,998 (15.5) |
 71–75 | 17,847 (15.4) |
 76–80 | 20,596 (17.8) |
 81–85 | 24,119 (20.8) |
  ≥ 86 | 35,216 (30.4) |
Index fracture by siteb | |
 Hip | 31,613 (27.3) |
 Wrist (distal radius, or both distal radius and ulna) | 17,859 (15.4) |
 Clavicle/ribs/sternum | 14,559 (12.6) |
 Humerus | 13,237 (11.4) |
 Tibia/fibula/knee (including medial and lateral malleolus) | 10,894 (9.4) |
 Pelvis | 8328 (7.2) |
 Vertebral (clinical) | 7721 (6.7) |
 Radius/ulna (proximal, midshaft, or distal ulna only) | 4828 (4.2) |
 Multisite | 3735 (3.2) |
 Femur | 3002 (2.6) |
Index fracture at any site by yearb | |
 2011 | 25,154 |
 2012 | 26,045 |
 2013 | 27,969 |
 2014 | 29,385 |
 2015b | 7223 |
Index fragility fracture treatment location | |
 Urban | 103,720 (89.6) |
 Rural | 10,626 (9.2) |
 Missing | 1430 (1.2) |
Respiratory conditionsc | |
 Asthma | 17,538 (15.1) |
 COPD | 33,485 (28.9) |
Inflammatory conditionsc | |
 RA | 4459 (3.9) |
 Psoriasis | 8076 (7.0) |
 SPA | 5084 (4.4) |
 Osteoarthritis | 88,223 (76.2) |
Cancerc | 8390 (7.2) |
Chronic kidney diseasec | 13,757 (11.9) |
Diabetesc | 35,434 (30.6) |
Vascular eventsc | |
 MI | 8175 (7.1) |
 Stroke or Cerebrovascular Events | 35,030 (30.3) |
Dementiac | 24,092 (20.8) |
OP treatmentd | |
 Any OP treatment | 32,757 (28.3) |
 Bisphosphonate | 29,030 (25.1) |
 Denosumab | 1578 (1.4) |
 HRT | 3597 (3.1) |
 Raloxifene | 656 (0.6) |
 Teriparatide | 0 (0) |
Steroid used | 3340 (2.9) |
Opioid used | 34,834 (30.1) |